Skip to content
Buy This GLP
← Research
Evidence

Japan's GLP-1 Treatment Cap: Weight Regain After a Mandated Stop

In a Japanese cohort studied under time-limited treatment rules, 21 of 22 patients with two-month follow-up regained weight after the mandated stop.

Editorial profile: Wesley JenkinsBuy This GLP Editorial Team6 min read
Weight change against month −6, when the rule starts0%start-14.4%cap-7%washoutAt six months after stopping, only 12 had follow-up data.

The guide to GLP-1 prepayment explains why the duration of a payment commitment can differ from the duration of treatment. In this small Japanese cohort, a policy set the stopping point [1]. Much of the other evidence comes from randomized withdrawal trials or databases that capture people who stopped for different reasons.

During treatment, mean weight change reached a partial plateau across months 10 to 14 at -16.3%, -16.1% and -15.5%, and stood at -16.0% at the month-16 endpoint. Then the cap took effect. Of the patients followed past it, 21 of 22 had regained weight within two months and 10 of 12 within six.

Relative to the baseline six months before treatment, the study reported mean changes of −14.4% at month 16 and −7.0% at month 22. Follow-up at month 22 included 12 patients. The authors offer this as a basis for examining whether a mandated stop is compatible with obesity being a chronic condition, which is a careful way of putting a pointed question.

The mandated waiting period produced its own finding. During the required six-month lifestyle phase before any drug was allowed, the post-surgery rescue cohort gained weight (+2.28 kg on average, with 69% gaining) while the primary cohort stayed roughly stable (-0.65 kg, p = 0.004). The groups differed in treatment history. The separate guide to GLP-1 prior authorization describes the delays reported by patients seeking coverage in the United States.

For a self-pay buyer in a market with no such rule, the transferable point is about planning rather than policy. A fixed-term plan or prepaid supply can end before you have a plan for continuing care. Discuss continuity with your prescriber before committing to a term. Pricing a course as a finite purchase and pricing it as an ongoing one are different decisions, as why falling prices and annual plans do not mix sets out.

Frequently asked

What happened after the mandated stop?
Of the patients followed past it, 21 of 22 had regained weight within two months and 10 of 12 within six. Mean change against the start went from -14.4% at month 16 to -7.0% at month 22.
How large was the study?
104 patients prospectively followed in one program, with 30 at the month-16 treatment endpoint and 22 and 12 at the two post-cessation checks. The fractions are small and the percentages should be read accordingly.
Did the required lifestyle phase help?
Not for everyone. The post-surgery rescue cohort gained an average 2.28 kg during it, with 69% gaining, while the primary cohort stayed roughly stable.

Sources

  1. [1] Inamine S, Uesato Y (2026). GLP-1 Receptor Agonist Therapy for Obesity Under Japan's Optimal Use Guideline: A Prospective Real-World Study of Lifestyle Pre-Treatment, Time-Limited Treatment Cap, and Post-Cessation Regain Diabetes, Obesity and Metabolism. PMID 42552238

Where to get it

Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

Open the price desk →

More in Evidence